Guillain-Barré Syndrome is the Most Likely Diagnosis
This clinical presentation is classic for Guillain-Barré syndrome (GBS), not myasthenia gravis (MG). The combination of recent gastroenteritis followed by ascending weakness (legs → arms) with tingling sensations fits the typical GBS pattern, whereas MG would present very differently 1.
Why This is GBS, Not MG
Classic GBS Features Present:
- Preceding infection: About two-thirds of GBS patients report infection symptoms within 6 weeks before onset, with gastroenteritis being a common trigger 1
- Ascending pattern: Weakness starting in legs and progressing to arms is the hallmark presentation of classic sensorimotor GBS 1
- Sensory symptoms: Tingling (distal paresthesias) accompanying or following weakness is typical 1
- Timing: Disease onset is acute/subacute, with patients typically reaching maximum disability within 2 weeks 1
Why NOT Myasthenia Gravis:
MG presents with fatigable, fluctuating weakness that is:
- Ocular/bulbar predominant: Ptosis, diplopia, dysphagia, dysarthria are the cardinal features 2, 3
- Proximal > distal: More proximal than distal weakness 3
- No sensory symptoms: MG does not cause tingling or sensory loss 3
- Pattern: Descending or cranial nerve involvement first, not ascending from legs 3
- No infectious trigger pattern: MG doesn't typically follow gastroenteritis
Critical Diagnostic Steps
Immediate Workup Required:
- Neurological examination: Check for areflexia/hyporeflexia (present in most GBS patients at presentation) 1
- Respiratory function monitoring: Measure negative inspiratory force (NIF) and vital capacity (VC) - 20% of GBS patients develop respiratory failure 1
- Lumbar puncture: Look for albuminocytologic dissociation (elevated CSF protein with normal cell count) - classic but can be normal early in disease 1
- Nerve conduction studies/EMG: Demonstrates peripheral nerve dysfunction and distinguishes GBS subtypes (AIDP, AMAN, AMSAN) 1
- Anti-ganglioside antibodies: Consider testing, though limited clinical value in typical cases 4
Red Flags for Respiratory Compromise:
- Monitor for dyspnea, inability to count to 20 in one breath, weak cough
- Serial NIF and VC measurements
- Dysautonomia (blood pressure/heart rate instability) is common 1
Immediate Management Algorithm
If unable to walk unaided (most critical decision point):
- Admit to hospital with ICU capability 2, 3
- Start treatment within 2 weeks of symptom onset 1:
- Monitor respiratory function frequently - intubation may be needed 1
- Daily neurologic assessments 2, 3
If still able to walk unaided:
- Close monitoring with serial examinations
- Treatment may still be indicated if progression occurs 4
Important Clinical Pitfalls
Don't Miss Concurrent MG-GBS:
While extremely rare, the two conditions can coexist 5, 6, 7. If patient develops:
- Ptosis or diplopia
- Fatigable weakness pattern
- Consider testing for anti-AChR antibodies and repetitive nerve stimulation 5, 7
However, this is exceedingly uncommon (only 15 reported cases in literature through 2016) 5, and should not delay GBS treatment.
Timing Considerations:
- Progression >4 weeks: Consider alternative diagnosis or acute-onset CIDP (occurs in ~5% initially diagnosed as GBS) 1, 4
- Maximum disability <24 hours or >4 weeks: Alternative diagnoses should be considered 1
Treatment Errors to Avoid:
- Don't use corticosteroids alone - not effective for idiopathic GBS 2, 3, 4
- Don't combine PE followed immediately by IVIG - PE will remove the immunoglobulin 2, 4
- Don't delay treatment waiting for confirmatory tests if clinical picture is clear 1
Prognosis
- Most patients reach maximum disability within 2 weeks 1
- 60-80% walk independently at 6 months 1
- Recovery can continue >3 years after onset 1
- Mortality 3-10% even with optimal care 1
- Use modified Erasmus GBS Outcome Score (mEGOS) to predict individual outcomes 1, 4
The key is early recognition and prompt immunotherapy to prevent respiratory failure and improve functional outcomes 1, 4.